Metabolic Volumetric Parameters in ¹¹C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer

Table 1

Clinical characteristics and PET/MR imaging parameters for the patients.

Variables	Descriptive statistics
Age (years)	70 (52–84)
<60.0	2 (6.5%)
60.0–69.9	11 (35.5%)
70.0–79.9	17 (54.8%)
≥80	1 (3.2%)
PSA (ng/ml)	30.56 (4.5–591.9)
<10	2 (6.5%)
10.0–20.0	6 (19.4%)
20.1–50.0	11 (35.5%)
50.1–100.0	3 (9.7%)
>100.0	9 (29.0%)
Gleason score	8 (6–10)
6	5 (16.1%)
7	9 (29.0%)
8	8 (25.8%)
9	6 (19.4%)
10	3 (9.7%)
Primary T
T2	4 (12.9%)
T3a	5 (16.1%)
T3b	6 (19.4%)
T4	16 (51.6%)
Regional lymph node metastasis
No	17 (54.8%)
Yes	14 (45.2%)
Distant metastasis
No	15 (48.4%)
Yes	16 (51.6%)
Clinical stage
IIB	2 (6.5%)
III	7 (22.6%)
IV	22 (71.0%)
PET parameters
SUVmax	6.36 (4.30–19.43)
SUVmean	3.63 (2.99–8.03)
MTV	14.42 (1.14–156.70)
UVP	54.97 (4.14–860.33)
MRI DCE parameters
Ktransmax (1/min)	310.00 (110.00–3993.00)
Ktranskur	3.38 (1.64–54.62)
Kepmax (1/min)	229.00 (66.00–4000.00)
Kepkur	3.16 (1.73–1640.82)
iAUCmax	1140.00 (635.00–3398.00)
iAUCkur	2.83 (1.64–11.32)
MRI ADC parameters
ADCmin (µm^2/s)	17.00 (1.00–485.00)
ADCmean (µm^2/s)	1002.78 (674.72–1357.42)
ADCkur (µm^2/s)	3.17 (2.40–5.65)

Descriptive statistics are presented as either median (range) or (%). Five patients showed both nonregional lymph node and bone metastasis. PSA, prostate-specific antigen.